Brief: Enveric Biosciences Updates Key Data Underpinning Selection Of Eb-003
03/01/2024 13:27
Jan 3 (Reuters) - Enveric Biosciences Inc ENVB.O :
* ENVERIC BIOSCIENCES UPDATES KEY DATA UNDERPINNING
SELECTION OF
EB-003 AS LEAD DRUG CANDIDATE FROM EVM301 SERIES
* ENVERIC TO INITIATE PRECLINICAL DEVELOPMENT OF EB-003 IN
2024 IN
PREPARATION FOR IND SUBMISSION
Source text for Eikon: ID:nBw8J9zmca
Further company coverage: ENVB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003